Lyell Immunopharma
South San Francisco, California, United States · Biotechnology, Health Care, Therapeutics · 279 employees
Lyell Immunopharma, Inc. is a clinical-stage biotechnology company specializing in next-generation cell therapies for cancer patients. It is publicly listed on Nasdaq under the symbol LYEL. The company aims to bring meaningful and durable clinical benefit to patients by focusing on next-generation CAR T-cell therapies and proprietary technologies designed to generate longer-lasting, functional T c
Funding history
- Funding Round — $493.0M — Mar 2020
Recent signals
- Oct 31, 2025: SEC 8-K (5.02): On October 31, 2025, Lyell Immunopharma, Inc. appointed Lynn Seely, M.D., the current President and Chief Executive Officer, as the interim principal financial officer. Additionally, Veronica Sanchez Bulis was appointed as the principal accounting officer. This change reflects a strategic move within the company's management as it positions itself for future financial oversight amidst ongoing developments. Dr. Seely's prior background is outlined in the company's definitive proxy statement from April 21, 2025, indicating he has substantial experience relevant to this role.
- Jun 09, 2025: Lyell Immunopharma Appoints David Shook as Chief Medical Officer and Mark Meltz as General Counsel
- Jan 09, 2025: Launched Lyell Immunopharma, Inc. Announces Plans for Next-Generation CAR T-Cell Therapy IMPT-314 at JP Morgan Healthcare Conference.
- Oct 31, 2024: Acquired Lyell Immunopharma Completes Acquisition of ImmPACT Bio to Strengthen Clinical Pipeline
- Mar 20, 2020: Raised $493.0M
See plans & pricing → Track Lyell Immunopharma’s funding, hiring, and signals — with verified contacts — on Fundz.